Rebuttal: disputes Sikiric anti-tumor claims for BPC-157
Jozwiak et al./PMC/2025
Why It Matters
Scientific rebuttal challenging the anti-tumor claims made for BPC-157. Part of an active academic dispute about whether BPC-157 has anti-cancer or pro-cancer properties.
Key Findings
- Challenges claims that BPC-157 has anti-tumor properties
- Notes that anti-tumor evidence relies on a single unreplicated 2004 cell-line study
Read the Paper↗PMC12567171